Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients

• Main Authors: Takahiro Einama (Author), Yoji Yamagishi (Author), Yasuhiro Takihata (Author), Takafumi Suzuki (Author), Tamio Yamasaki (Author), Yuichi Hirose (Author), Kazuki Kobayashi (Author), Naoto Yonamine (Author), Ibuki Fujinuma (Author), Takazumi Tsunenari (Author), Makiko Koga (Author), Yusuke Ishibashi (Author), Ken Nagata (Author), Takehiro Shiraishi (Author), Akiko Nakazawa (Author), Toshimitsu Iwasaki (Author), Eiji Shinto (Author), Kimi Kato (Author), Kimiya Sato (Author), Hideki Ueno (Author), Yoji Kishi (Author), Hitoshi Tsuda (Author)
• Format: Book
• Published: BMC, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Abstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox's multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer.

Item Description

10.1186/s40364-021-00335-3
2050-7771